Literature DB >> 22385129

Low castes have poor access to visceral leishmaniasis treatment in Bihar, India.

F Pascual Martínez1, A Picado, P Roddy, P Palma.   

Abstract

OBJECTIVES: Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically related to the caste system. In this study, we evaluated whether people from low socio-economic strata had difficulties accessing VL treatment in Bihar. As a secondary outcome, we evaluated whether people delaying their VL treatment had poorer clinical indicators at admission.
METHODS: Data on 2187 patients with VL treated by Médecins Sans Frontières (MSF) in Vaishali district from July 2007 to December 2008 were analysed. Patients who reported having onset of symptoms ≥8 weeks before admission were defined as 'late presenters'. Logistic regression models were used to evaluate whether low castes had higher risk to be 'late presenters' compared to the rest of castes and whether 'late presenters' had poorer indicators at admission (i.e. haemoglobin level, spleen size).
RESULTS: After adjusting for age, gender and distance to VL treatment facility, Mushars (the lowest caste in Bihar) had twice the odds to be 'late presenters' compared to the rest of castes (OR 2.05, 95% CI: 1.24-2.38). Subjects that had VL symptoms for ≥8 weeks had a larger spleen and lower haemoglobin level than those that were treated earlier.
CONCLUSION: Low castes have poor access to VL treatment in Bihar, and late presenters have poorer clinical indicators at admission. These findings have implications at individual and community levels and should stimulate targeted VL control programmes to ensure that marginalized communities in Bihar are properly treated.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22385129     DOI: 10.1111/j.1365-3156.2012.02960.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  16 in total

1.  Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System.

Authors:  Paritosh Malaviya; Albert Picado; Epco Hasker; Bart Ostyn; Sangeeta Kansal; Rudra Pratap Singh; Ravi Shankar; Marleen Boelaert; Shyam Sundar
Journal:  Int J Epidemiol       Date:  2014-09-02       Impact factor: 7.196

Review 2.  Social and Economic Burden of Human Leishmaniasis.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Am J Trop Med Hyg       Date:  2016-01-19       Impact factor: 2.345

3.  Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.

Authors:  Sakshi Mohan; Paul Revill; Stefano Malvolti; Melissa Malhame; Mark Sculpher; Paul M Kaye
Journal:  PLoS Negl Trop Dis       Date:  2022-06-13

4.  Visceral leishmaniasis in rural bihar, India.

Authors:  Epco Hasker; Shri Prakash Singh; Paritosh Malaviya; Albert Picado; Kamlesh Gidwani; Rudra Pratap Singh; Joris Menten; Marleen Boelaert; Shyam Sundar
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

Review 5.  Liposomal amphotericin B as a treatment for human leishmaniasis.

Authors:  Manica Balasegaram; Koert Ritmeijer; Maria Angeles Lima; Sakib Burza; Gemma Ortiz Genovese; Barbara Milani; Sara Gaspani; Julien Potet; François Chappuis
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-20       Impact factor: 4.191

6.  Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India.

Authors:  Jan P Boettcher; Yubaraj Siwakoti; Ana Milojkovic; Niyamat A Siddiqui; Chitra K Gurung; Suman Rijal; Pradeep Das; Axel Kroeger; Megha R Banjara
Journal:  BMC Infect Dis       Date:  2015-02-06       Impact factor: 3.090

Review 7.  Revisiting public health challenges in the new millennium.

Authors:  Ts Anish; Pr Sreelakshmi
Journal:  Ann Med Health Sci Res       Date:  2013-07

8.  Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.

Authors:  Sakib Burza; Prabhat K Sinha; Raman Mahajan; María Angeles Lima; Gaurab Mitra; Neena Verma; Manica Balasegaram; Manica Balasegarem; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

9.  Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

Authors:  Sakib Burza; Prabhat K Sinha; Raman Mahajan; María Angeles Lima; Gaurab Mitra; Neena Verma; Manica Balasegaram; Manica Balsegaram; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

Review 10.  Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review.

Authors:  Grace Grifferty; Hugh Shirley; Jamie McGloin; Jorja Kahn; Adrienne Orriols; Richard Wamai
Journal:  Res Rep Trop Med       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.